Melanoma Research Institute of Excellence
Support the Melanoma Research Institute of Excellence

Contact

Name: Mitchell Berkowitz
Position: Program Manager
Organization: Melanoma Research Institute of Excellence
Contact Number(s):

Contact

Name: Shingo Sato
Positions:
  • Associate Program Manager
  • Director of Database Design and Utilization
Organization: Melanoma Research Institute of Excellence
Contact Number(s):

Clinical Trials

Marlana Orloff, MD

Principal Investigator

A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer
APG-115-US-002: A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
A Phase 1/2 Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
A Phase I/Ib, Open-Label Study of the Pressure-Enabled hepatic Artery Infusion of SD-101, a TLR9 Agonist, Alone or in Combination with Intravenous Checkpoint Blockade in Adults with Metastatic Uveal Melanoma
IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-Line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma
(Neo)adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-Line Therapy in  HLA-A2 Negative Metastatic Uveal Melanoma

Takami Sato, MD, PhD

Principal Investigator

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers
A Study for the In Vitro Detection and Analysis of Circulating Biomarkers in Melanoma Patients from a Blood Draw

Carin Gonsalves, MD

Principal Investigator

Chemoembolization of Uveal Melanoma Hepatic Metastases using 300mg of BCNU Dissolved in Lipiodol followed by Gelfoam Embolization

Rino Seedor, MD

Principal Investigator

A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors
A Phase II Trial of Defactinib (VS-6063) Combined with VS-6766 (CH5126766) in Patients with Metastatic Uveal Melanoma
A Phase II Study of Concurrent Stereotactic Body Radiotherapy with Relatlimab and Nivolumab in Patients with Metastatic Uveal Melanoma
A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-risk Melanoma
Geospatial Distribution of Uveal Melanoma
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma
A Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients with Resected Mucosal Melanoma
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with PreviouslyUntreated Metastatic or Unresectable Melanoma; RELATIVITY-127
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma (PET-Stop)  
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Clinical Research Staff
Go Back to Melanoma Research Institute of Excellence